Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Pre-Market Technical Scan on Biotech Equities -- Ignyta, Pluristem Therapeutics, Ritter Pharma, and Tenax Therapeutics

Wall St. Equities
Posted on: 08 Jan 18
Pre-Market Technical Scan on Biotech Equities -- Ignyta, Pluristem Therapeutics, Ritter Pharma, and Tenax Therapeutics

PR Newswire

NEW YORK, Jan. 8, 2018

NEW YORK, Jan. 8, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community.  Today we are offering reports on RXDX, PSTI, RTTR, and TENX which can be accessed for free by signing up to On Friday, January 05, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of last Friday's session. The NASDAQ Composite ended the day at 7,136.56, up 0.83%; the Dow Jones Industrial Average edged 0.88% higher, to finish at 25,295.87; and the S&P 500 closed at 2,743.15, up 0.70%. This Monday morning, looks at the performance of these four Biotechnology stocks: Ignyta Inc. (NASDAQ: RXDX), Pluristem Therapeutics Inc. (NASDAQ: PSTI), Ritter Pharmaceuticals Inc. (NASDAQ: RTTR), and Tenax Therapeutics Inc. (NASDAQ: TENX). All you have to do is sign up today for this free limited time offer by clicking the link below.


On Friday, shares in San Diego, California headquartered Ignyta Inc. recorded a trading volume of 4.26 million shares, which was above their three months average volume of 2.38 million shares. The stock ended the session flat at $27.00. The Company's shares have gained 72.52% in the last month, 103.77% over the previous three months and 382.14% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 54.08% and 131.30%, respectively. Moreover, shares of Ignyta, which engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases, have a Relative Strength Index (RSI) of 84.08.

On December 28th, 2017, research firm Cantor Fitzgerald downgraded the Company's stock rating from 'Overweight' to 'Neutral' while revising its previous target price from $23 a share to $27 a share. Get the full research report on RXDX for free by clicking below at:

Pluristem Therapeutics

Haifa, Israel-based Pluristem Therapeutics Inc.'s stock closed the day 0.70% higher at $1.44 with a total trading volume of 59,265 shares. The Company's shares have advanced 0.70% in the past month. The stock is trading above its 200-day moving average by 3.62%. Additionally, shares of Pluristem Therapeutics, which together with its subsidiary, Pluristem Ltd, operates as a bio-therapeutics company in Israel, have an RSI of 49.73. Free research on PSTI can be accessed at:

Ritter Pharmaceuticals

Shares in Los Angeles, California headquartered Ritter Pharmaceuticals Inc. recorded a trading volume of 181,781 shares. The stock ended last Friday's trading session 1.39% lower at $0.32. The Company's shares have advanced 4.17% in the past month. The stock is trading below its 50-day moving averages by 2.73%. Furthermore, shares of Ritter Pharma, which develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, have an RSI of 50.19. Sign up today for the free research report on RTTR at:

Tenax Therapeutics

Morrisville, North Carolina headquartered Tenax Therapeutics Inc.'s stock finished Friday's session flat at $0.47 with a total trading volume of 137,259 shares. The Company's shares have advanced 22.17% in the last month and 23.68% over the previous three months. The stock is trading above its 50-day moving average by 9.58%. Additionally, shares of Tenax Therapeutics, which focuses on the identification, development, and commercialization of a portfolio of products for the critical care market in the US and Canada, have an RSI of 53.47. Wall St. Equities' research coverage also includes the downloadable free report on TENX at:


Wall St. Equities :

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


View original content:

SOURCE Wall St. Equities

PR Newswire

Last updated on: 08/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.